TPIP is a new version of an existing pulmonary arterial hypertension medication called treprostinil. It is designed as a “prodrug” – meaning it becomes active only after the body processes it. The key advantage is that TPIP can be taken as a dry powder in a capsule-based inhaler, once daily.
In a 102-patient phase 2b trial, TPIP exceeded expectations on both major measures used to evaluate pulmonary arterial hypertension treatments:
- Pulmonary vascular resistance (PVR): TPIP reduced this key measure of lung blood vessel pressure by 35% compared to placebo
- Six-minute walk test: Patients could walk an additional 35.5 meters compared to those on placebo
The strong results suggest TPIP could offer patients a more convenient once-daily treatment option while potentially being more effective than existing therapies. To be followed.
Read more at this link